FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129772791> ?p ?o ?g. }

• W2129772791 endingPage "338" @default.
• W2129772791 startingPage "333" @default.
• W2129772791 abstract "A phase II multicentre double blind placebo controlled study in 1993 showed that short term treatment (10 days) with recombinant human DNase I (rhDNase) was safe and improved pulmonary function in patients with cystic fibrosis with stable stage lung disease. A six month open label treatment study was conducted in some of the patients who participated in the short term study to assess the medium term effects of rhDNase.Patients who completed the phase II study and were stable for 14 days prior to treatment were eligible. They were treated with rhDNase 2.5 mg twice daily for six months and reviewed at regular intervals to assess safety and efficacy.Fifty nine patients (31M,28F) of age range 16-55 years were recruited. Mean baseline values for forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were 41.5% and 72.4% of predicted, respectively. The mean increase in FEV1 over the first month of treatment was 13.1% (range 12-14.1%) and then stabilised at 6.2% (4.6-7.8%) for the subsequent five months. FVC was similarly improved. Administration of rhDNase improved the severity of dyspnoea, cystic fibrosis related symptoms, and the modified Taussig/NIH score (not statistically significant). Fifty seven of the 59 patients completed the study; two died from progression of their pulmonary disease unrelated to treatment with rhDNase. The adverse events and intercurrent illnesses were no different from those expected in a cystic fibrosis population. Pharyngitis was the only possible drug related adverse event which occurred at least once in 14% of patients during the six month period.Administration of rhDNase was safe, well tolerated, and improved pulmonary function in patients with cystic fibrosis. When rhDNase was stopped at day 169 there was a deterioration in pulmonary function and dyspnoea score." @default.
• W2129772791 created "2016-06-24" @default.
• W2129772791 creator A5036400895 @default.
• W2129772791 creator A5042431195 @default.
• W2129772791 creator A5066218661 @default.
• W2129772791 creator A5081740012 @default.
• W2129772791 creator A5090245576 @default.
• W2129772791 date "1995-04-01" @default.
• W2129772791 modified "2023-09-26" @default.
• W2129772791 title "Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I." @default.
• W2129772791 cites W106701955 @default.
• W2129772791 cites W1892403664 @default.
• W2129772791 cites W1997182007 @default.
• W2129772791 cites W2023546954 @default.
• W2129772791 cites W2027494131 @default.
• W2129772791 cites W2030381943 @default.
• W2129772791 cites W2045196836 @default.
• W2129772791 cites W2049355530 @default.
• W2129772791 cites W2060633742 @default.
• W2129772791 cites W2094395573 @default.
• W2129772791 cites W2150399236 @default.
• W2129772791 cites W2156361445 @default.
• W2129772791 cites W2333398204 @default.
• W2129772791 cites W2336714143 @default.
• W2129772791 cites W4244598283 @default.
• W2129772791 cites W4249200669 @default.
• W2129772791 doi "https://doi.org/10.1136/thx.50.4.333" @default.
• W2129772791 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/474268" @default.
• W2129772791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7785003" @default.
• W2129772791 hasPublicationYear "1995" @default.
• W2129772791 type Work @default.
• W2129772791 sameAs 2129772791 @default.
• W2129772791 citedByCount "47" @default.
• W2129772791 countsByYear W21297727912012 @default.
• W2129772791 countsByYear W21297727912013 @default.
• W2129772791 countsByYear W21297727912014 @default.
• W2129772791 countsByYear W21297727912016 @default.
• W2129772791 countsByYear W21297727912018 @default.
• W2129772791 countsByYear W21297727912021 @default.
• W2129772791 countsByYear W21297727912023 @default.
• W2129772791 crossrefType "journal-article" @default.
• W2129772791 hasAuthorship W2129772791A5036400895 @default.
• W2129772791 hasAuthorship W2129772791A5042431195 @default.
• W2129772791 hasAuthorship W2129772791A5066218661 @default.
• W2129772791 hasAuthorship W2129772791A5081740012 @default.
• W2129772791 hasAuthorship W2129772791A5090245576 @default.
• W2129772791 hasBestOaLocation W21297727911 @default.
• W2129772791 hasConcept C126322002 @default.
• W2129772791 hasConcept C141071460 @default.
• W2129772791 hasConcept C142724271 @default.
• W2129772791 hasConcept C165637977 @default.
• W2129772791 hasConcept C197934379 @default.
• W2129772791 hasConcept C204787440 @default.
• W2129772791 hasConcept C27081682 @default.
• W2129772791 hasConcept C2776178081 @default.
• W2129772791 hasConcept C2776938444 @default.
• W2129772791 hasConcept C2777714996 @default.
• W2129772791 hasConcept C2908647359 @default.
• W2129772791 hasConcept C3018587741 @default.
• W2129772791 hasConcept C55520419 @default.
• W2129772791 hasConcept C71924100 @default.
• W2129772791 hasConcept C75603125 @default.
• W2129772791 hasConcept C90924648 @default.
• W2129772791 hasConcept C99454951 @default.
• W2129772791 hasConceptScore W2129772791C126322002 @default.
• W2129772791 hasConceptScore W2129772791C141071460 @default.
• W2129772791 hasConceptScore W2129772791C142724271 @default.
• W2129772791 hasConceptScore W2129772791C165637977 @default.
• W2129772791 hasConceptScore W2129772791C197934379 @default.
• W2129772791 hasConceptScore W2129772791C204787440 @default.
• W2129772791 hasConceptScore W2129772791C27081682 @default.
• W2129772791 hasConceptScore W2129772791C2776178081 @default.
• W2129772791 hasConceptScore W2129772791C2776938444 @default.
• W2129772791 hasConceptScore W2129772791C2777714996 @default.
• W2129772791 hasConceptScore W2129772791C2908647359 @default.
• W2129772791 hasConceptScore W2129772791C3018587741 @default.
• W2129772791 hasConceptScore W2129772791C55520419 @default.
• W2129772791 hasConceptScore W2129772791C71924100 @default.
• W2129772791 hasConceptScore W2129772791C75603125 @default.
• W2129772791 hasConceptScore W2129772791C90924648 @default.
• W2129772791 hasConceptScore W2129772791C99454951 @default.
• W2129772791 hasIssue "4" @default.
• W2129772791 hasLocation W21297727911 @default.
• W2129772791 hasLocation W21297727912 @default.
• W2129772791 hasLocation W21297727913 @default.
• W2129772791 hasLocation W21297727914 @default.
• W2129772791 hasOpenAccess W2129772791 @default.
• W2129772791 hasPrimaryLocation W21297727911 @default.
• W2129772791 hasRelatedWork W2031286892 @default.
• W2129772791 hasRelatedWork W2046354137 @default.
• W2129772791 hasRelatedWork W2048132946 @default.
• W2129772791 hasRelatedWork W2110528741 @default.
• W2129772791 hasRelatedWork W2129772791 @default.
• W2129772791 hasRelatedWork W2130947272 @default.
• W2129772791 hasRelatedWork W2169123370 @default.
• W2129772791 hasRelatedWork W2405417907 @default.
• W2129772791 hasRelatedWork W3094217367 @default.
• W2129772791 hasRelatedWork W3122557007 @default.

• next